-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Recent News from ILCN
-
Looking Ahead to the IASLC | ASCO 2025 North America Conference on Lung Cancer
Conference Chair Dr. Christine Bestvina shares what attendees can look forward to at this year’s must-attend event in Chicago.
-
Tobacco Control Policy in Low- and Middle-Income Countries: The Case of India and South Africa
Drs. Surender Kashyap and Lekan Ayo-Yusuf discuss how stronger enforcement and collaboration are key to reducing the global burden of lung cancer in countries where tobacco-related deaths remain high.
-
Early Data Suggest Primary Tumor Resection Following EGFR TKI Treatment May Help Delay Disease Progression in Metastatic NSCLC
PTR-1 trial results, recently presented by Dr. Pei-Hsing Chen, showed a higher pathological complete response for exon 19 deletions and greater survival benefit from the intervention for L858R mutations.
-
New Data Strengthen the Link Between Air Pollution Exposure and Increased Lung Cancer Risk
Researchers addressed the role of PM2.5 in lung cancer initiation and screening outcomes, as well as how genetic and air pollution scores can identify those at an increased risk.
-
In Brief for November 19, 2025
The US FDA confirms the use of pembrolizumab and berahyaluronidase alfa-pmph as an injectable therapy for solid tumor indications.
-
IASLC Launches Beta Version of VIKTOR
The Basic and Translational Science Committee’s new tool aims to unify available digital knowledge about preclinical models into one accessible, reliable system.
-
Patient Charts: How to Carefully Manage Patient Access to Health Information
Advocate Angus Pratt explores the pros and cons of patient access to electronic health records and discusses how the emergence of AI—with human oversight—could offer a way to navigate this complex issue.
-
CAN-2409 Plus Valacyclovir Extends Survival in ICI-Refractory NSCLC
The final OS and safety data support the development of a phase III randomized clinical trial, Dr. Charu Aggarwal said.
-
Using Early ctDNA, Study Findings Inform Prognostic Model
New data presented by Dr. Nan Bi shed new light on ctDNA status to identify patients who would benefit from consolidation ICI and to predict survival outcomes.
-
In Brief for November 5, 2025
FDA clears a combination medication for extensive-stage small cell lung cancer for patients whose disease has not progressed after first-line induction therapy.